Loading
Loading
Research Overview
Proapoptotic peptide that selectively targets vasculature supplying white adipose tissue by binding prohibitin on fat-cell blood vessels, inducing targeted apoptosis of the adipose vasculature and reducing fat mass in preclinical models.
Overview
Adipotide consists of two functional domains: a targeting sequence binding to PROHIBITIN on white adipose tissue endothelial cells, and a pro-apoptotic KLAKLAK domain. Preclinical research has used this compound to study the consequences of selectively inducing apoptosis in the blood vessel cells supplying white adipose tissue in animal models.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, adipotide (ftpp) peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Proapoptotic peptide that selectively targets vasculature supplying white adipose tissue by binding prohibitin on fat-cell blood vessels, inducing targeted apoptosis of the adipose vasculature and reducing fat mass in preclinical models.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.